CAS: 157335-92-7; 4-Methylpyrimidine-5-Carboxylic Acid
该化合物是其火水环结构,这是一种六人组成的热循环芳香环,含有1和3号位置的两个氮原子. 这种化合物具有5号位置的碳球酸功能组和4号位置的甲基组(-CH3),通常是白到白的,非白的固体的,并且由于存在碳仁酸组而溶于极地溶剂中.该化合物可能具有酸性,使其得以参与各种化学反应,例如酯化或恐吓.其结构特征表明有可能在制药,农用化学品或作为有机合成的建筑块中应用.此外,该环中存在的氮可能有助于其生物活动,从而引起对医药化学的兴趣.许多丙米丁衍生物与许多丙米丁衍生物一样,它也可能起到协调化学中的结链或作为合成复杂分子的中间体的作用.
- 英文名称4-Methylpyrimidine-5-Carboxylic Acid
- 中文名称4-甲基-嘧啶-5-羧酸
- IUPAC名称4-methylpyrimidine-5-carboxylic acid
- 其它别名4-甲基-5-嘧啶甲酸; 5-Pyrimidinecarboxylic Acid, 4-Methyl- (9Ci)
- CAS编号157335-92-7
- MFCD编号:MFCD08361632
- EINECS号:800-993-8
- 分子式:C6H6N2O2分子量:138.12
- 产品CID: 786262
- 产品分类有机原料→分子砌块→芳杂环类化合物→嘧啶类化合物
相似化合物
110960-73-1 1150633-16-1 157335-93-8物理性质
MSDS等安全信息
欧盟法规
C&L通报上下游产品
CAS号110960-73-1 4-甲基嘧啶-5-甲酸乙酯合成工艺路线路线简述
- 合成目标产物 5-Pyrimidinecarboxylicacid,4-Methyl- 主要起始原料 Ethyl-4-Methyl Pyrimidine-5-Carboxylate
- (文献来源)合成步骤主要原料 Ethyl-4-Methyl Pyrimidine-5-Carboxylate
📜(Z)-Methyl 2-((Dimethylamino)Methylene)-3-Oxobutanoate置于sodium Hydroxide,Sodium Ethanolate体系中,用 乙醇 用作溶剂,化学反应 19.0H,反应生成4-甲基嘧啶-5-甲酸
参考文献:Kress,Thomas J.,Heterocycles,1994,Vol. 38,# 6,P. 1375-1382
标题:Kress,Thomas J.,Heterocycles,1994,Vol. 38,# 6,P. 1375-1382
海关参考信息
- 2905110000-甲醇
2912110000-甲醛
2915110000-甲酸 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-8188113-B2
优先权日:2006-09-14
标 题 :Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases
发明人：FLYNN DANIEL L; PETILLO PETER A; KAUFMAN MICHAEL D; PATT WILLIAM C
权利人:FLYNN DANIEL L; PETILLO PETER A; KAUFMAN MICHAEL D; PATT WILLIAM C; DECIPHERA PHARMACEUTICALS INC
摘要:The present invention relates to novel dihydropyridopyrimidinyl, dihydronaphthyridinyl, and related compounds which are kinase inhibitors and modulator useful for the treatment of various diseases. More particularly, the invention is concerned with such compounds, kinase/compound adducts, methods of treating diseases, and methods of synthesis of the compounds. Preferably, the compounds are useful for the modulation of kinase activity of Raf kinases and disease polymorphs thereof. Compounds of the present invention find utility in the treatment of mammalian cancers and especially human cancers including but not limited to malignant melanoma, colorectal cancer, ovarian cancer, papillary thyroid carcinoma, non small cell lung cancer, and mesothelioma. Compounds of the present invention also find utility in the treatment of rheumatoid arthritis and retinopathies including diabetic retinal neuropathy and macular degeneration.
